Construction and Validation of a Novel Cuproptosis-Related Seven-lncRNA Signature to Predict the Outcomes, Immunotherapeutic Responses, and Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma.

Haoxun Zhang Zikuan Ning Bowen Wang Yiwen Liu Boju Tao Guoling Zhang Hua Liu Chunyang Wang

Published in: Disease markers (2023)

In summary, we generated a CR-lncRNA risk signature that may be utilized to predict outcomes in patients with ccRCC and responsiveness to immunotherapy and targeted treatment, potentially serving as a reference for clinical personalized medicine.

Keyphrases

long non coding rna
cancer therapy
metabolic syndrome
adipose tissue
glycemic control
high density